CYBN - Psychedelics research amendments advance in House committee
2023-09-26 13:17:43 ET
More on psychedelic drug development
- Atai Life Sciences: RL-007, Targeting Schizophrenia Subpopulation With No FDA Approved Therapies
- Psychedelic Stocks = Super-Risky Biotechs Low On Cash. Make Small Bets.
- COMPASS: The Landscape Is Changing Quickly; Risk Is Up And Potential Down
- Psychedelic Stocks: Don't Bet On Just 1 Company
- With ecstasy a potential PTSD therapy, psychedelic treatments could take off
For further details see:
Psychedelics research amendments advance in House committee